Immune Design to Present at Jefferies 2017 London Healthcare Conference
November 13, 2017 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that Carlos Paya,...
Immune Design Announces Multiple Presentations at CTOS and SITC Highlighting the Breadth of Existing & Future Product Candidates
November 07, 2017 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced seven...
Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 01, 2017 16:02 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today reported financial results...
Immune Design to Report Third Quarter 2017 Financial Results & Provide Corporate Update
October 27, 2017 08:00 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 27, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report...
Immune Design Prices $80.0 Million Public Offering of Common Stock
October 24, 2017 20:13 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today the pricing of an underwritten public offering of 19,500,000 shares of...
Immune Design Announces Proposed Public Offering of Common Stock
October 23, 2017 16:14 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Immune Design Corp. (Nasdaq:IMDZ) announced today that it plans to offer and sell up to 16,000,000 shares of its common...
Immune Design Announces G100’s Receipt of Orphan Drug Designation by the EMA for the Treatment of Follicular Non-Hodgkin’s Lymphoma
October 19, 2017 16:05 ET
|
Immune Design Corp.
SEATTLE and SOUTH SAN FRANCISCO, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that the European...
Immune Design Announces Positive FDA Feedback on Phase 3 Clinical Trial Design for CMB305 in Synovial Sarcoma Patients
October 16, 2017 16:15 ET
|
Immune Design Corp.
CMB305 Monotherapy vs. Placebo in the Maintenance SettingPFS Analysis for Potential Full Approval as Early as 24 Months After Study StartConference Call and Webcast Tomorrow at 5:30am PT/8:30am ET ...
Immune Design Announces Four Upcoming Presentations at the SITC 32nd Annual Meeting
September 25, 2017 08:00 ET
|
Immune Design Corp
SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that four...
New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit and Immune Response
September 08, 2017 04:00 ET
|
Immune Design Corp
Phase 2 Interim Analysis Data Presented at ESMO 2017 Congress SEATTLE and SOUTH SAN FRANCISCO, Calif., Sept. 08, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy...